MedTrace Logo

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

NCT07230106 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2026-03-03

No results posted yet for this study

Summary

This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.

Conditions

Interventions

DRUG

HS-20093 for Injection

HS-20093 for injection.

DRUG

SHR3680 Tablet

SHR3680 tablet.

DRUG

Abiraterone Tablet

Abiraterone tablet.

DRUG

SHR2554 Tablet

SHR2554 tablet.

DRUG

Enzalutamide Tablet

Enzalutamide tablet.

DRUG

Darotamine Capsule

Darotamine capsule.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-08
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07230106 on ClinicalTrials.gov